sb 216763 and urea
sb 216763 has been researched along with urea in 4 studies
Compound Research Comparison
| Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) | Studies (urea) | Trials (urea) | Recent Studies (post-2010) (urea) |
|---|---|---|---|---|---|
| 342 | 0 | 225 | 45,450 | 2,047 | 9,188 |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Caricasole, A; Gaviraghi, G; Terstappen, GC | 1 |
| Bauchwitz, RP; Chen, S; Jope, RS; Min, WW; Sikorski, C; Yan, Q; Yuskaitis, CJ | 1 |
| Dawson, LA; Kalinichev, M | 1 |
| Abe, K; Aiba, H; Aoki, Y; Araki, Y; Bolidong, D; Domoto, T; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Minamoto, T; Miwa, S; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N; Yonezawa, H | 1 |
Other Studies
4 other study(ies) available for sb 216763 and urea
| Article | Year |
|---|---|
The Wnt signaling pathway as a target for the treatment of neurodegenerative disorders.
Topics: Animals; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Homeostasis; Humans; Indoles; Lithium Chloride; Maleimides; Models, Biological; Nervous System; Neurodegenerative Diseases; Pyridines; Pyrimidines; Signal Transduction; Thiazoles; Urea; Wnt Proteins | 2006 |
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antimanic Agents; Brain; Citrates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Exploratory Behavior; Fragile X Mental Retardation Protein; Gene Expression Regulation; Glycogen Synthase Kinase 3; Indoles; Lithium Chloride; Male; Maleimides; Mice; Mice, Knockout; Pyridines; Seizures; Serine; Thiazoles; Urea | 2009 |
Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania.
Topics: Amphetamine; Animals; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Blood-Brain Barrier; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycogen Synthase Kinase 3; Humans; Indoles; Male; Maleimides; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Motor Activity; Reproducibility of Results; Thiadiazoles; Thiazoles; Urea | 2011 |
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase 4; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Injections, Intraperitoneal; Maleimides; Mice; Phosphorylation; RNA Interference; Sarcoma, Synovial; Thiazoles; Up-Regulation; Urea; Xenograft Model Antitumor Assays | 2020 |